X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13251) 13251
Magazine Article (11) 11
Book / eBook (9) 9
Book Chapter (7) 7
Dissertation (7) 7
Conference Proceeding (4) 4
Streaming Video (4) 4
Web Resource (4) 4
Publication (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12388) 12388
science & technology (10881) 10881
life sciences & biomedicine (9987) 9987
hepacivirus - genetics (6444) 6444
male (6056) 6056
female (5866) 5866
hepacivirus - drug effects (5526) 5526
hepatitis c virus (5466) 5466
middle aged (5109) 5109
hepatitis c (5065) 5065
antiviral agents - therapeutic use (4872) 4872
adult (4725) 4725
hepatitis c, chronic - drug therapy (4275) 4275
genotype (3693) 3693
gastroenterology & hepatology (3606) 3606
treatment outcome (2995) 2995
hepatitis (2951) 2951
drug therapy, combination (2779) 2779
hepatitis c - drug therapy (2709) 2709
hepatitis c, chronic - virology (2690) 2690
virology (2634) 2634
ribavirin - therapeutic use (2543) 2543
interferon-alpha - therapeutic use (2512) 2512
aged (2503) 2503
antiviral agents - pharmacology (2479) 2479
infectious diseases (2380) 2380
hepatitis c - virology (2287) 2287
health aspects (2285) 2285
interferon (2198) 2198
hepacivirus - physiology (1978) 1978
virus diseases (1958) 1958
hepacivirus - isolation & purification (1847) 1847
viruses (1753) 1753
antiviral agents (1707) 1707
viral load (1649) 1649
rna, viral - blood (1630) 1630
infections (1606) 1606
pharmacology & pharmacy (1582) 1582
hepacivirus (1578) 1578
antiviral agents - administration & dosage (1573) 1573
ribavirin (1559) 1559
hepacivirus - immunology (1456) 1456
animals (1451) 1451
analysis (1427) 1427
recombinant proteins (1421) 1421
microbiology (1400) 1400
polyethylene glycols - therapeutic use (1393) 1393
antiviral agents - adverse effects (1389) 1389
risk factors (1352) 1352
liver (1274) 1274
immunology (1255) 1255
genetic aspects (1216) 1216
digestive system diseases (1206) 1206
virus replication - drug effects (1206) 1206
hcv (1193) 1193
care and treatment (1182) 1182
biological response modifiers (1153) 1153
ribavirin - administration & dosage (1073) 1073
gastroenterology and hepatology (1062) 1062
research (1051) 1051
hepatitis c, chronic - complications (1041) 1041
research article (1035) 1035
hepatitis c - complications (1011) 1011
young adult (1003) 1003
rna (1000) 1000
interferon-alpha - administration & dosage (995) 995
medicine (979) 979
abridged index medicus (976) 976
hepatitis c - epidemiology (972) 972
cell line (953) 953
retrospective studies (948) 948
viral nonstructural proteins - antagonists & inhibitors (933) 933
time factors (913) 913
drug therapy (909) 909
hiv (895) 895
adolescent (887) 887
science & technology - other topics (872) 872
viral nonstructural proteins - genetics (871) 871
multidisciplinary sciences (859) 859
hepacivirus - pathogenicity (858) 858
liver diseases (843) 843
hepacivirus - classification (821) 821
rna, viral - genetics (818) 818
recombinant proteins - therapeutic use (789) 789
genotypes (765) 765
antiviral agents - chemistry (760) 760
hepacivirus - enzymology (760) 760
patients (760) 760
genotype & phenotype (754) 754
hepatology (752) 752
cell line, tumor (729) 729
science (725) 725
hiv infections - complications (719) 719
proteins (715) 715
prospective studies (714) 714
hepatitis c - immunology (711) 711
biochemistry & molecular biology (708) 708
ribavirin - adverse effects (705) 705
viral nonstructural proteins - metabolism (704) 704
liver cirrhosis (700) 700
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13004) 13004
Chinese (108) 108
Japanese (96) 96
German (72) 72
Russian (62) 62
Spanish (57) 57
Portuguese (45) 45
French (39) 39
Polish (32) 32
Hungarian (18) 18
Korean (10) 10
Italian (7) 7
Hebrew (5) 5
Turkish (5) 5
Dutch (4) 4
Norwegian (3) 3
Arabic (2) 2
Croatian (2) 2
Czech (2) 2
Danish (2) 2
Romanian (2) 2
Serbian (2) 2
Ukrainian (2) 2
Bosnian (1) 1
Finnish (1) 1
Icelandic (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
PloS one, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, pp. e0133236 - e0133236
Serum levels of the interferon (IFN)-stimulated chemokine CXCL10 are increased during chronic HCV infection and associate with outcome of IFN-based therapy.... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Recurrence | Interferons | Humans | Fluorenes - therapeutic use | Dipeptidyl Peptidase 4 - blood | Hepatitis C, Chronic - virology | Male | Adult | Female | Hepacivirus - physiology | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Virus Replication - drug effects | Chemokine CXCL10 - blood | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Dipeptidyl Peptidase 4 - genetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Convalescence | Chemokine CXCL10 - genetics | Protein Processing, Post-Translational | Hepatitis C, Chronic - genetics | Viral Load - drug effects | Infection | Care and treatment | Analysis | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Therapy | Laboratories | Chronic infection | Critical care | Amino acids | Infections | Ribavirin | Clinical outcomes | Proteins | Genotype & phenotype | Hepatitis | Immunology | Hepatology | Post-translation | Pretreatment | Drug dosages | Genotypes | Statistical analysis | Liver diseases | Dendritic cells | Serum levels | Studies | Infectious diseases | CXCL10 protein | Biomarkers | Chemokines | Index Medicus | Virus Replication/drug effects | Viral Load/drug effects | Dipeptidyl Peptidase 4/blood | Dipeptidyl Peptidase 4/genetics | Chemokine CXCL10/blood | Hepatitis C, Chronic/blood | Life Sciences | Hepatitis C, Chronic/drug therapy | Hepatitis C, Chronic/virology | Hepatitis C, Chronic/genetics | Chemokine CXCL10/genetics | Benzimidazoles/therapeutic use | Hepacivirus/physiology | Fluorenes/therapeutic use | Antiviral Agents/therapeutic use | Sofosbuvir/therapeutic use | Hepacivirus/drug effects | Ribavirin/therapeutic use
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2015, Volume 373, Issue 8, pp. 705 - 713
... interactions with concomitant antiretroviral drugs. 11 – 13 The first oral HCV direct-acting antiviral drugs — the NS3/4A protease inhibitors boceprevir and telaprevir... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | HIV-1 | Humans | Middle Aged | Drug Resistance, Viral | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Viral Load | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Fluorenes - pharmacokinetics | Hepacivirus - isolation & purification | Anti-Retroviral Agents - therapeutic use | Antiviral Agents - therapeutic use | Benzimidazoles - pharmacokinetics | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | HIV Infections - drug therapy | Uridine Monophosphate - pharmacokinetics | Sofosbuvir | Care and treatment | Research | Hepatitis C virus | HIV infection | Emtricitabine | Headache | Antiretroviral drugs | Inhibitor drugs | Diarrhea | Fatigue | Patients | Efavirenz | Studies | Tenofovir | Cirrhosis | Genotype & phenotype | Hepatitis | Human immunodeficiency virus--HIV | Hepatitis C | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 09/2015, Volume 149, Issue 3, pp. 649 - 659
..., few clinical trials have included patients with decompensated liver disease and the effect of sustained virologic response on liver-related function and outcomes... 
Gastroenterology and Hepatology | Liver Transplantation | Decompensated Cirrhosis | Hepatitis C Virus Infection | Fibrosing Cholestatic Hepatitis | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | United States | Humans | Middle Aged | Fluorenes - therapeutic use | Liver Cirrhosis - mortality | Hepacivirus - genetics | Male | Cholestasis, Intrahepatic - drug therapy | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - mortality | Time Factors | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Cholestasis, Intrahepatic - virology | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Liver Cirrhosis - drug therapy | Liver Cirrhosis - diagnosis | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Disease Progression | Cholestasis, Intrahepatic - mortality | Hepacivirus - enzymology | Liver Cirrhosis - virology | Cholestasis, Intrahepatic - diagnosis | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Drug Combinations | Care and treatment | Liver diseases | Hepatitis C virus | Hepatitis C | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 07/2013, Volume 13, Issue 7, pp. 597 - 605
Summary Background Rates of sustained virological response (SVR) to peginterferon–ribavirin are low in patients with hepatitis C virus (HCV) genotype 1 and... 
Infectious Disease | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Recombinant Proteins - adverse effects | Viral Load | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Drug Therapy, Combination - adverse effects | HIV-1 - isolation & purification | Placebos - adverse effects | Ribavirin - administration & dosage | Adult | Female | Placebos - administration & dosage | Proline - administration & dosage | Hepacivirus - isolation & purification | Double-Blind Method | Proline - analogs & derivatives | HIV Infections - virology | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | HIV Infections - complications | Aged | Hepacivirus - classification | Interferon-alpha - adverse effects | Medical colleges | Interferon alpha | Clinical trials | HIV (Viruses) | Biological response modifiers | Ribavirin | Viral antigens | Virus diseases | Genetic aspects | Product development | Drug therapy | Hepatitis C virus | HIV infection | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2015, Volume 373, Issue 8, pp. 714 - 725
Journal Article